|
Noubar B. Afeyan, Ph.D., Chairman, Ensemble Discovery – Managing Partner and CEO, Flagship
Ventures
Noubar Afeyan is a partner and co-founder of Flagship Ventures. He currently
serves as a Director for Flagship portfolio companies Adnexus Therapeutics,
Affinnova, BG Medicine, Codon Devices, Ensemble Discovery, Genstruct,
Helicos BioSciences, LS9 and T2 Biosystems. He is also a member of the
Boston University Board of Overseers and a member of several advisory
boards including the Whitehead Institute at MIT, the Harvard-MIT Division
of Health Sciences and Technology (HST).
Prior to Flagship, Noubar was the Founder, Chairman, and CEO of PerSeptive
Biosystems, a leader in the bio-instrumentation field. He also served
as Chairman of the Board of ChemGenics Pharmaceuticals, a spin-off company
of PerSeptive. After PerSeptive's acquisition by Applera Corporation,
he was Senior Vice President and Chief Business Officer of Applera. He
has also been a founding team member, investor and active board member/advisor
of Antigenics, Color Kinetics and EXACT Sciences. A Senior Lecturer at
MIT in the Sloan School of Management as well as the Biological Engineering
Division, Noubar has authored numerous scientific publications and patents.
Noubar holds a Ph.D. in Biochemical Engineering from MIT.
Jean-Jacques Bienaimé – Chief Executive Officer,
BioMarin
Jean-Jacques Bienaimé is chief executive officer and member of
the board of directors of BioMarin. He is a member of the board of directors
of NeurogesX, Inc. and Saegis Pharmaceuticals, Inc., and is a member
of the advisory board of Bellevue Asset Management's BioVentures II fund.
Prior to joining BioMarin in April 2005, Jean-Jacques served as chairman,
chief executive officer, and president of Genencor, a biotechnology company
focused on industrial bioproducts and targeted cancer biotherapeutics.
From 1998 to late 2002, Jean-Jacques served as chairman, chief executive
officer and president of Sangstat Medical Corporation, an immunology-focused
biotechnology company. From 1992 to 1998, Jean-Jacques held several senior
management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis).
Earlier in his career, he worked at Genentech, Inc. where he was involved
in the launch of tissue plasminogen activator (t-PA) for the treatment
of heart attacks.
Jean-Jacques holds an M.B.A from the Wharton School at the University
of Pennsylvania and an undergraduate degree in economics from the Ecole
Superieure de Commerce de Paris.
Douglas G. Cole, M.D. – General Partner, Flagship Ventures
Douglas Cole is a partner at Flagship Ventures, where he focuses on Life
Science investments. He has led investments in CombinatoRx, Alinea
Pharmaceuticals, Tetraphase, Alvine
Pharmaceuticals, and Concert
Pharmaceuticals. He co-founded Ensemble
Discovery with Noubar Afeyan and Professor David Liu of Harvard
University, and served as CEO of the company in its initial stages.
He currently serves on the Boards of Directors of Ensemble Discovery,
Tetraphase, Concert Pharmaceuticals, AVEO
Pharmaceuticals, CGI
Pharmaceuticals, and Morphotek,
and is an Observer on the Board of Directors of Alinea, and Alvine.
Prior to Flagship, Douglas held senior management positions at Vertex Pharmaceuticals
and Cytotherapeutics. He obtained post-graduate training in medicine
at the Johns Hopkins Hospital in Baltimore, MD and in neurology the Massachusetts
General Hospital in Boston, MA, where was appointed Instructor in Neurology
at Harvard Medical School and an Assistant in Neurology at the Massachusetts
General Hospital.
Douglas holds an AB magna cum laude with High Distinction in English from
Dartmouth College, and an MD from the University of Pennsylvania School
of Medicine.
Doug M. Fambrough, Ph.D. – General Partner, Oxford Bioscience Partners
Since joining Oxford in 1999, Doug has specialized in financing innovative life science technology companies. In addition to Ensemble Discovery, his current projects include Dicerna Pharmaceuticals, a second generation RNAi company that he co-founded; Cambrios Technologies, a developer of biologically-inspired electronic materials for the display industry; Xencor, a protein therapeutics company that engineers antibody Fc regions to enhance potency; and Solstice Neurosciences, a neurology specialty pharmaceutical company. His past investments include RNA interference pioneer Sirna Therapeutics (acquired by Merck), and the ultra-high-throughput DNA sequencing equipment company Solexa (acquired by Illumina).
Prior to Oxford, Doug was a genomic researcher at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in genetics from the University of California, Berkeley.
Robert T. Nelsen – Co-founder and Managing Director, ARCH
Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture
Partners, where he focuses on biotechnology, pharmaceuticals, and micro-
and nanotechnology. He has played a significant role in the early sourcing,
financing and development of more than thirty companies and is a director
of Adolor, Elixir Pharmaceuticals, Ensemble Discovery, NeurogesX, Kythera
BioPharmaceuticals, and Ikaria. He previously served on the boards of
Trubion Pharmaceuticals, Surface Logix, NetBot, Everyday Learning, Spaltudaq,
Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and
Classmates.com, among others. He also served as a director of the Fred
Hutchinson Cancer Research Institute.
Robert holds an M.B.A. from The University of Chicago and a B.S. in
Economics and Biology from the University of Puget Sound.
Anna Protopapas – Senior Vice President, Corporate Development,
Millennium Pharmaceuticals
Anna Protopapas is Senior Vice President of Corporate Development at
Millennium Pharmaceuticals. She joined Millennium in 1997 and has been
a key driving force in forging alliances that have brought over $2 billion
in funding to Millennium, including alliances with Johnson & Johnson,
Aventis and Abbott. She has overseen the formation of development stage
in-licensing and out-licensing collaborations including the collaborations
with ILEX, Xenova, Xoma and Taisho. Prior to Millennium, Anna held various
positions in engineering, marketing and business development.
Anna holds B.S.E. and M.S.E degrees from Princeton University and MIT,
respectively, and an M.B.A. from Stanford Business School.
Michael D. Taylor, Ph.D. – Chief Executive Officer
Mike joined Ensemble Discovery as President and CEO in July of 2007 with more
than 20 years experience in the pharmaceutical industry. Recently, Mike
was Senior Vice President for Pfizer’s Global R&D division responsible
for global project and portfolio management. In other positions with
Pfizer (and previously Warner-Lambert/Parke-Davis), Mike led early and late-stage
development projects across multiple therapeutic areas, including Lipitor® and
Neurontin®. His career includes extensive experience in drug discovery,
licensing and business development, and managing R&D alliances with pharmaceutical
and biotech partners. In addition to his R&D experience he is active
in investor development, government affairs and public policy affecting the
pharmaceutical industry. Until 2003 he was Adjunct Professor of Medicinal Chemistry
at the College of Pharmacy at the University of Michigan, where he was active
in teaching medicinal chemistry and biopharmaceutics. Mike has authored or
coauthored 65 manuscripts and published abstracts and holds 6 patents.
Mike holds a Ph.D. in Medicinal Chemistry from the State University
of New York at Buffalo and was awarded an NIH postdoctoral fellowship
in natural products synthesis and structure elucidation at the University
of Pennsylvania.
[ ]
|
